A Gold Coast company that has developed a body scanner which measures changes in body fat and muscle is working towards an ASX debut next month as it cashes in on the rapid adoption of weight loss drugs like Ozempic.
Evolt 360 will embark on an investor roadshow next month after closing a $20 million pre-IPO funding round led by Bell Potter, alongside its existing major investors Regal Partners, Washington H. Soul Pattinson and Perennial Partners.
Loading...
Tess Bennett is a technology reporter with The Australian Financial Review, based in the Brisbane newsroom. She was previously the work & careers reporter. Connect with Tess on Twitter. Email Tess at tess.bennett@afr.com
